Overview

Location [1]
12q13.2
Pathway
Receptor tyrosine kinase/growth factor signaling
Protein [2]
Receptor tyrosine-protein kinase erbB-3
Synonyms [1]
ErbB-3, p85-sErbB3, c-erbB3, c-erbB-3, p180-ErbB3, MDA-BF-1, p45-sErbB3, HER3, erbB3-S, LCCS2

Erb-b2 receptor tyrosine kinase 3 (ERBB3) is a gene that encodes a receptor tyrosine kinase in the epidermal growth factor family. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.

ERBB3 is altered in 3.16% of all cancers with colorectal adenocarcinoma, breast carcinoma, non-small cell lung carcinoma, uterine corpus neoplasm, and bladder carcinoma having the greatest prevalence of alterations [3].

ERBB3 GENIE Cases - Top Diseases

The most common alterations in ERBB3 are ERBB3 Mutation (3.12%), ERBB3 Amplification (0.30%), ERBB3 V104M (0.17%), ERBB3 E928G (0.13%), and ERBB3 V104L (0.11%) [3].

ERBB3 GENIE Cases - Top Alterations

Significance of ERBB3 in Diseases

Malignant Solid Tumor +

Urothelial Carcinoma +

Colorectal Carcinoma +

Breast Carcinoma +

Non-Small Cell Lung Carcinoma +

Bladder Carcinoma +

Endometrial Carcinoma +

Gastric Carcinoma +

Anaplastic Astrocytoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Melanoma +

Head And Neck Squamous Cell Carcinoma +

Ovarian Carcinoma +

Glioblastoma +

Head And Neck Carcinoma +

Lymphoma +

Sarcoma +

Pancreatic Carcinoma +

Biliary Tract Neoplasm +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.